PharmGen Science Balance Sheet Health
Financial Health criteria checks 4/6
PharmGen Science has a total shareholder equity of ₩228.2B and total debt of ₩37.0B, which brings its debt-to-equity ratio to 16.2%. Its total assets and total liabilities are ₩335.9B and ₩107.7B respectively. PharmGen Science's EBIT is ₩9.1B making its interest coverage ratio 2.2. It has cash and short-term investments of ₩37.4B.
Key information
16.2%
Debt to equity ratio
₩37.02b
Debt
Interest coverage ratio | 2.2x |
Cash | ₩37.44b |
Equity | ₩228.21b |
Total liabilities | ₩107.71b |
Total assets | ₩335.92b |
Recent financial health updates
Recent updates
PharmGen Science's (KRX:004720) Shareholders Have More To Worry About Than Only Soft Earnings
Mar 27Is Wooridul Pharmaceutical (KRX:004720) A Risky Investment?
Mar 21Investors Who Bought Wooridul Pharmaceutical (KRX:004720) Shares Five Years Ago Are Now Up 55%
Jan 19Does The Market Have A Low Tolerance For Wooridul Pharmaceutical Limited's (KRX:004720) Mixed Fundamentals?
Dec 21Are Wooridul Pharmaceutical's (KRX:004720) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 25Financial Position Analysis
Short Term Liabilities: A004720's short term assets (₩95.3B) exceed its short term liabilities (₩63.2B).
Long Term Liabilities: A004720's short term assets (₩95.3B) exceed its long term liabilities (₩44.5B).
Debt to Equity History and Analysis
Debt Level: A004720 has more cash than its total debt.
Reducing Debt: A004720's debt to equity ratio has reduced from 34% to 16.2% over the past 5 years.
Debt Coverage: A004720's debt is not well covered by operating cash flow (14.7%).
Interest Coverage: A004720's interest payments on its debt are not well covered by EBIT (2.2x coverage).